



Samrat Pharmachem Limited

Manufacturers & Exporters of Pharmaceutical Chemicals

Regd. Office & Factory

Plot No. A2/3445, GIDC,
Phase 4, Ankleshwar – 393 002,
Gujarat, India
Tel : +91-7045456789 / 7046456789
Web: www.samratpharmachem.com

CIN: L24230GJ1992PLC017820

Corporate Office

701/702, Business Square,
M. A. Road, Andheri (West),
Mumbai – 400 058, India
Tel : (91-22) 26701050 / 1 / 2 / 3
Email: contact@samratpharmachem.in

February 14, 2023

To,
Department of Corporate Services,
BSE Limited
P J Towers,
Dalal Street,
Mumbai - 400 001.

Scrip Code: 530125

Dear Sir,

Sub: Approval of Un-Audited Financial Results for the quarter ended December 31, 2022

We wish to inform you that the Board of Directors of the Company at its meeting held today i.e. Tuesday, February 14, 2023, the Board has considered and took on record the attached Un-Audited Standalone Financial Results of the Company for the quarter ended December 31, 2022, which is enclosed herewith along with the Limited Review Report of the Statutory Auditor of the Company.

The meeting of the Board of Directors of the Company commenced at 14:30 hrs and concluded at 16:00 hrs.

Kindly inform all your members.

Thanking you,

Yours faithfully,
For Samrat Pharmachem Limited

Nishant Kankaria
Company Secretary & Compliance Officer



Samrat Pharmachem Limited

Manufacturers & Exporters of Pharmaceutical Chemicals

Regd Office : Plot No. A2/3445, GIDC Phase 4, Ankleshwar - 393 002, Gujarat
 Corp Office : 701/702, Business Square, M. A. Road, Andheri (West), Mumbai - 400 058.
 CIN : L24230GJ1992PLC017820

Statement of Standalone Unaudited Results for the Quarter ended 31 December, 2022

(Rs. In Lakhs)

Particulars	Quarter ended			Year to date ended		Previous Year Ended
	31-Dec-22	30-Sep-22	31-Dec-21	31-Dec-22	31-Dec-21	31-Mar-22
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1 (a). Net Income from Sales / Services	8,398.95	7,111.75	5,534.39	24,161.37	16,165.39	22,181.17
(b). Other Operating Income	11.59	15.93	23.42	30.05	46.47	55.08
Total Income	8,410.54	7,127.68	5,557.81	24,191.42	16,211.86	22,236.25
2. Expenditure						
a) Cost of materials consumed	8,083.83	6,874.54	4,422.04	22,525.39	14,131.66	19,023.42
b) Purchase of Traded Goods	0.00	0.00	0.00	0.00	0.00	0.00
c) Change in Inventories of Finished Goods and Work-in-Progress	-243.01	-821.34	29.50	-1,477.92	81.13	-33.33
d) Employee Costs	45.51	43.17	46.86	129.82	124.72	177.47
e) Interest	60.26	23.60	12.55	106.47	50.63	67.45
f) Depreciation & Amortisation expense	16.11	15.99	15.14	47.86	44.39	59.47
g) Other Expenses	170.44	189.68	175.81	527.67	410.49	579.28
(i) Manufacturing Expenses	95.77	88.75	109.72	280.52	275.64	376.66
(ii) Administration Expenses	37.67	29.36	26.46	99.05	58.91	93.35
(iii) Selling & Distribution Expenses	37.00	71.57	39.63	148.10	75.94	109.27
Total	8,133.14	6,325.64	4,701.90	21,859.29	14,843.02	19,873.76
3. Profit before exceptional & extraordinary items & tax	277.40	802.04	855.91	2,332.13	1,368.84	2,362.49
4. Exceptional Items	0.00	0.00	0.00	0.00	0.00	-2.34
5. Profit before extraordinary items & tax	277.40	802.04	855.91	2,332.13	1,368.84	2,360.15
6. Extraordinary items	0.00	0.00	0.00	0.00	0.00	0.00
7. Profit before tax	277.40	802.04	855.91	2,332.13	1,368.84	2,360.15
8. Tax expense						
a) Current Tax	-39.91	-221.65	-211.58	-574.50	-335.83	-638.82
b) Deferred Tax	-27.90	10.89	0.36	-20.09	-13.99	-2.84
Total Tax Expense	-67.81	-210.76	-211.22	-594.59	-349.82	-641.66
9. Profit (Loss) for the period after tax	209.59	591.28	644.69	1,737.54	1,019.02	1,718.49
10. Other Comprehensive Income (OCI)						
a(i) Items that will not be re-classified to profit and loss	0.00	0.00	0.00	0.00	0.00	0.00
(ii) Income tax relating to items that will not be re-classified to profit and loss	0.00	0.00	0.00	0.00	0.00	0.00
b(i) Items that will be re-classified to profit and loss	0.00	0.00	0.00	0.00	0.00	0.00
(ii) Income tax relating to items that will be re-classified to profit and loss	0.00	0.00	0.00	0.00	0.00	0.00
Total Other comprehensive income, net of income tax	0.00	0.00	0.00	0.00	0.00	0.00
11. Total Comprehensive Income for the period	209.59	591.28	644.69	1,737.54	1,019.02	1,718.49
12. Paid-up Equity Share Capital (Face Value Rs.10)	308.97	308.97	308.97	308.97	308.97	308.97
13. Earnings per equity share						
a) Basic	6.78	19.14	20.87	56.24	32.98	55.62
b) Diluted	6.78	19.14	20.87	56.24	32.98	55.62

Notes:

- The above results were reviewed by the Audit Committee of the Board of Directors.
- The Statutory Auditors have carried out a limited review of the results for the quarter ended 31 December, 2022.
- The above results have been taken on record by the Board of Directors at its Meeting held on Tuesday, 14 February 2023 at the Corporate Office of the Company.
- The Company has adopted Indian Accounting Standards ('Ind AS') notified by the Ministry of Corporate Affairs with effect from 01 April 2017 (with a transition date of 01 April 2016). Accordingly the financial results for the quarter ended 31 December 2022 have been prepared in accordance with Companies (Indian Accounting Standard) Rules, 2015 as prescribed under section 133 of the Companies Act, 2013.
- The Company manufactures pharmaceutical chemicals, which is a single business segment.
- Figures for the previous period have been regrouped / reclassified, wherever necessary.



By order of the Board of Directors
 For Samrat Pharmachem Limited

Rajesh Mehta
 Director

Place : Mumbai
 Date : 14 February 2023



Independent Auditor's Review Report on Quarterly and Year-to-date Unaudited Financial Results of the Company pursuant to the regulation 33 of SEBI (Listing obligations and Disclosure Requirements) Regulation, 2015, as amended

To the Board of Directors of Samrat Pharmachem Limited

1. We have reviewed the accompanying statement of unaudited financials result of Samrat Pharmachem Limited, for the Quarter ended 31st December, 2022 and year to date results for the period from 01 April 2022 to 31 December 2022 (the "statement") attached herewith, being submitted by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015, as amended.
2. This statement, which is the responsibility of the Company's Management and approved by the Board of Directors / Committee of Board of Directors has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" (Ind AS 34), prescribed under section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the statement based on our review.
3. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim financial information performed by Independent Auditor of the entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free of material misstatements. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with standards on auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standards (Ind AS) specified under section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Shah & Savla LLP
Chartered Accountants
Firm Reg: No.:109364W/W100143


CA. Mulesh M. Savla
(Partner)
Membership No. 038404



UDIN: 23038404BGZHGX7397

Place: Mumbai

Date: 14th February, 2023

Office : 201-RNJ Corporate, Jawahar Road, Ghatkopar (East), Mumbai - 400077, INDIA.

T: (022) 6153 5500 / 2501 0700 | E: info@shahnsavla.com | W: www.shahnsavla.com